glp 1 discontinuation Patients with diabetes who remained on GLP-1 drugs had lower cardiovascular risk Proportion of Patients Who Discontinued

The Chronos Advantage Customized dosage adjustments based on your progress In-person and virtual follow-ups for continued care Holistic programs that integrate nutrition, exercise, and accountability Transparent, affordable pricing

NASDAQ: DXCM Key Data Points Plenty of growth runway DexCom's addressable market is underpenetrated

Alternative pharmacotherapy options Beyond GLP-1 RAs, current FDA-approved pharmacotherapies for chronic weight management include orlistat (a lipase inhibitor that reduces fat absorption), phentermine-topiramate (a sympathomimetic appetite suppressant combined with a gamma-aminobutyric acid receptor modulator), naltrexone-bupropion (an opioid antagonist combined with a dopamine/norepinephrine reuptake inhibitor), and setmelanotide (a melanocortin-4 receptor agonist)

While this may be beneficial for those managing blood glucose naturally, it may create issues for those on GLP-1 agonists

Goodnick PJ

Redox Biol (2020) 31:101435